Li Chan, Tian Wei, Zhao Feng, Li Meng, Ye Qin, Wei Yuquan, Li Tao, Xie Ke
Department of Oncology, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Department of Oncology, People's Hospital of Xinjin, Chengdu, Sichuan 611430, P.R. China.
Oncotarget. 2018 Oct 19;9(82):35293-35299. doi: 10.18632/oncotarget.24293.
Cancer in the elderly has become a common problem due in part to the increase in life expectancy. Compared to younger counterparts, the biological characteristics of tumors and their responsiveness to therapy may differ in elderly patients, and the elderly also can have a decreased tolerance to anticancer therapy. In addition, there is less evidence from clinical trials to guide physicians in treating aged patients with solid tumors. Thus, we often face a dilemma as to how actively to treat these patients and it would be highly useful to have a simple and powerful indicator of their prognosis. In this paper we evaluated the predictive value of the Systemic Immune-inflammation Index, SII, in determining the one-year survival and tumor differentiation status in elderly patients with newly diagnosed solid tumors.
A high SII > 390×10 cells/L was correlated with poor tumor differentiation (χ = 9.791, = 0.002) and poor one-year survival (χ = 7.658, = 0.006). Patients with low SII had improved survival and better tumor differentiation (Stage I-II). The SII was not associated with Ki-67 expression.
Data from 119 patients, 70 to 89 years of age with newly diagnosed solid tumors in 2014 were retrospectively analyzed. The patients were divided into two groups according to age: (1) 70-75 years of age and (2) over 75 years of age. We calculated SII from the equation, SII = P x N/L, where P, N and L are the preoperative peripheral blood platelet, neutrophil and lymphocyte counts per liter respectively. The optimum cutoff point for SII for a favorable prognosis was determined to be 390×10 cells/L. For evaluation of SII as a prognostic indicator, the patients were divided into high SII (> 390×10 cells/L) and low SII (≤ 390×10 cells/L) groups. Individual values were used to determine the relationship between SII and one-year survival, tumor differentiation and Ki-67 expression in the two age groups.
SII was a robust indicator of tumor differentiation and one-year survival in elderly patients with newly diagnosed solid tumors. Patients in the high SII group showed poor tumor differentiation and poor prognosis compared to patients with a low SII score.
由于预期寿命的增加，老年癌症已成为一个常见问题。与年轻患者相比，老年患者肿瘤的生物学特性及其对治疗的反应可能不同，而且老年人对抗癌治疗的耐受性也可能降低。此外，临床试验中指导医生治疗老年实体瘤患者的证据较少。因此，我们常常面临如何积极治疗这些患者的困境，而拥有一个简单且有力的预后指标将非常有用。在本文中，我们评估了全身免疫炎症指数（SII）在确定新诊断实体瘤老年患者一年生存率和肿瘤分化状态方面的预测价值。
高SII>390×10⁹细胞/L与肿瘤低分化（χ² = 9.791，P = 0.002）和一年生存率低（χ² = 7.658，P = 0.006）相关。SII低的患者生存率提高，肿瘤分化更好（I-II期）。SII与Ki-67表达无关。
回顾性分析2014年119例年龄在70至89岁之间新诊断实体瘤患者的数据。根据年龄将患者分为两组：（1）70-75岁和（2）75岁以上。我们根据公式SII = P×N/L计算SII，其中P、N和L分别是术前每升外周血血小板、中性粒细胞和淋巴细胞计数。确定SII预后良好的最佳截断点为390×10⁹细胞/L。为评估SII作为预后指标，将患者分为高SII（>390×10⁹细胞/L）和低SII（≤390×10⁹细胞/L）组。使用个体值确定两个年龄组中SII与一年生存率、肿瘤分化和Ki-67表达之间的关系。
SII是新诊断实体瘤老年患者肿瘤分化和一年生存率的有力指标。与SII评分低的患者相比，高SII组患者的肿瘤分化差，预后不良。
